Current issues in oncology drug development, with a focus on Phase II trials
about
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedRegulatory Forum Opinion Piece*: Veterinary Pathologists in Translational Pharmacology and Biomarker Integration in Drug Discovery and Development.Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and powerQuantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
P2860
Current issues in oncology drug development, with a focus on Phase II trials
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Current issues in oncology drug development, with a focus on Phase II trials
@ast
Current issues in oncology drug development, with a focus on Phase II trials
@en
type
label
Current issues in oncology drug development, with a focus on Phase II trials
@ast
Current issues in oncology drug development, with a focus on Phase II trials
@en
prefLabel
Current issues in oncology drug development, with a focus on Phase II trials
@ast
Current issues in oncology drug development, with a focus on Phase II trials
@en
P2860
P1476
Current issues in oncology drug development, with a focus on Phase II trials
@en
P2093
Jeremy M G Taylor
P2860
P304
P356
10.1080/10543400902802474
P577
2009-01-01T00:00:00Z